Randomised, Double-blind, Cross-over Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 2 Doses of Orally Inhaled BI 1744 CL, Each in Fixed Dose Combination (FDC) With 5 Microgram Tiotropium Bromide (Delivered by the Respimat® Inhaler) in Patients With COPD
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006615/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL
administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the
Respimat® inhaler, once daily for four weeks in patients with chronic obstructive pulmonary
disease (COPD).
提供机构：
Vivli
创建时间：
2021-01-27
